Novo Nordisk, Wegovy
EU regulator backs use of Novo's Wegovy for obesity-related heart condition
The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with obesity, the Danish drugmaker said on Thursday. This marks the regulator's second backing for a use of Wegovy beyond weight loss and further strengthens Novo's case that the medicine has multiple health benefits.
EMA CHMP recommends label update to Novo Nordisk’s Wegovy
Committee for Medicinal Products for Human Use (CHMP) has recommended an update to Novo Nordisk’s Wegovy (semaglutide 2.4 mg) label. This update in the European Union (EU) reflects new data indicating the product’s ability,
Novo Nordisk's Wegovy Recommended For Label Update To Reflect Heart Failure Benefits
The company noted that Wegovy is the first obesity medication to receive a positive opinion recommending a label update that reflects reduced symptoms and improved physical limitations and exercise function in people with obesity-related heart failure with preserved ejection fraction (HFpEF).
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human
Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity-Related Heart Failure
Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients.
Everyday Health8d
Wegovy May Reduce the Risk of Death From COVID-19, Study Suggests
those on Wegovy were 33 percent less likely to die of the illness than those who took the placebo. The findings were presented at the European Society of Cardiology (ESC) Conference 2024 in London ...
Regulatory Oversight News | Today's Latest Stories | Reuters
Reuters.com is your online source for the latest news stories and current events, ensuring our readers up to date with any breaking news developments ...
ABC News4d
European Union chief Ursula von der Leyen puts women in many of the top roles in her new Commission team
European Union chief Ursula von der Leyen puts women in many of the top roles in her new Commission team BRUSSELS -- European Union chief Ursula von der Leyen puts women in many of the top ...
WKBW10d
Weight-loss pill from Wegovy makers cut body weight by up to 13% in early trial
The early findings show a greater weight loss than those who took Wegovy during a similar time frame, who lost about 6%. The findings were presented at the European Association for the Study of ...
EU plans Sept 25 vote on raising tariffs on EVs from China, Bloomberg News reports
The European Union is aiming to hold a vote to introduce definitive tariffs on electric vehicles imported from China on Sept.
UPI12d
Wegovy, Ozempic may someday be available as monthly injection
researchers said in a presentation at the European Association for the Study of Diabetes' annual meeting in Madrid. Related Study: Using Ozempic, Wegovy won't increase risk of depression ...
Yahoo News12d
Wegovy, Ozempic may someday be available as monthly injection
A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month ... researchers said in a presentation at the European Association for the Study of ...